Acute Circulatory Failure in Severe Infection
Conditions
Interventions
Trial Group:Anisodamine hydrobromide injection 1.2~4.0mg/(kg*d)
Control Group:Individualized comprehensive treatment according to the disease
Sponsors
Beijing Chao-Yang Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients those who are clinically diagnosed with acute circulating failure in severe infection; 2. Aged 18-70 years male and female; 3. Obtain informed consent and signature of patient or guardian.
Exclusion criteria
Exclusion criteria: 1. Patients with poor prognosis and those who is likely to die within 24 hours, such as patients with severe craniocerebral injury, post-cardiopulmonary resuscitation, terminal malignant tumors, severe chronic systemic disease are excluded; 2. Patients with immunosuppression or using a continous dose of immunosuppressive agents are excluded; 3. Patients with a severe reduction in granulocytes or with granulocytic deficiency are excluded; 4. Patients with intracranial pressure increase and glaucoma, or at the acute stage of cerebral hemorrhage are excluded; 5. Patients with allergic constitution, allergy history of the the drug and food or allergic to the anisodamine hydrobromide are excluded; 6. Pregnant and lactating patients or those with a pregnancy plan are excluded; 7. Patients participated in other clinical trials in latest 3 months are excluded; 8. Other factors that the researchers consider unsuitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| cr;PaO2/FiO2%;ALT;TBil;AMY;cTnI;BNP;GCS;NE/NE%;PLT;cLac;BE;PCT;C-????;ESR; | — |
Secondary
| Measure | Time frame |
|---|---|
| BUN;urine volume;Electrolyte;Blood Routine;Blood Gas Analysis; | — |
Countries
China
Contacts
Public ContactShubin Guo
Beijing Chao-Yang Hospital
Outcome results
None listed